Cargando…

Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials

Imaging studies of FTD typically present group-level statistics between large cohorts of genetically, molecularly or clinically stratified patients. Group-level statistics are indispensable to appraise unifying radiological traits and describe genotype-associated signatures in academic studies. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenna, Mary Clare, Tahedl, Marlene, Lope, Jasmin, Chipika, Rangariroyashe H., Li Hi Shing, Stacey, Doherty, Mark A., Hengeveld, Jennifer C., Vajda, Alice, McLaughlin, Russell L., Hardiman, Orla, Hutchinson, Siobhan, Bede, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107414/
https://www.ncbi.nlm.nih.gov/pubmed/34882275
http://dx.doi.org/10.1007/s11682-021-00523-7
_version_ 1784708484831379456
author McKenna, Mary Clare
Tahedl, Marlene
Lope, Jasmin
Chipika, Rangariroyashe H.
Li Hi Shing, Stacey
Doherty, Mark A.
Hengeveld, Jennifer C.
Vajda, Alice
McLaughlin, Russell L.
Hardiman, Orla
Hutchinson, Siobhan
Bede, Peter
author_facet McKenna, Mary Clare
Tahedl, Marlene
Lope, Jasmin
Chipika, Rangariroyashe H.
Li Hi Shing, Stacey
Doherty, Mark A.
Hengeveld, Jennifer C.
Vajda, Alice
McLaughlin, Russell L.
Hardiman, Orla
Hutchinson, Siobhan
Bede, Peter
author_sort McKenna, Mary Clare
collection PubMed
description Imaging studies of FTD typically present group-level statistics between large cohorts of genetically, molecularly or clinically stratified patients. Group-level statistics are indispensable to appraise unifying radiological traits and describe genotype-associated signatures in academic studies. However, in a clinical setting, the primary objective is the meaningful interpretation of imaging data from individual patients to assist diagnostic classification, inform prognosis, and enable the assessment of progressive changes compared to baseline scans. In an attempt to address the pragmatic demands of clinical imaging, a prospective computational neuroimaging study was undertaken in a cohort of patients across the spectrum of FTD phenotypes. Cortical changes were evaluated in a dual pipeline, using standard cortical thickness analyses and an individualised, z-score based approach to characterise subject-level disease burden. Phenotype-specific patterns of cortical atrophy were readily detected with both methodological approaches. Consistent with their clinical profiles, patients with bvFTD exhibited orbitofrontal, cingulate and dorsolateral prefrontal atrophy. Patients with ALS-FTD displayed precentral gyrus involvement, nfvPPA patients showed widespread cortical degeneration including insular and opercular regions and patients with svPPA exhibited relatively focal anterior temporal lobe atrophy. Cortical atrophy patterns were reliably detected in single individuals, and these maps were consistent with the clinical categorisation. Our preliminary data indicate that standard T1-weighted structural data from single patients may be utilised to generate maps of cortical atrophy. While the computational interpretation of single scans is challenging, it offers unrivalled insights compared to visual inspection. The quantitative evaluation of individual MRI data may aid diagnostic classification, clinical decision making, and assessing longitudinal changes.
format Online
Article
Text
id pubmed-9107414
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-91074142022-05-16 Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials McKenna, Mary Clare Tahedl, Marlene Lope, Jasmin Chipika, Rangariroyashe H. Li Hi Shing, Stacey Doherty, Mark A. Hengeveld, Jennifer C. Vajda, Alice McLaughlin, Russell L. Hardiman, Orla Hutchinson, Siobhan Bede, Peter Brain Imaging Behav Original Research Imaging studies of FTD typically present group-level statistics between large cohorts of genetically, molecularly or clinically stratified patients. Group-level statistics are indispensable to appraise unifying radiological traits and describe genotype-associated signatures in academic studies. However, in a clinical setting, the primary objective is the meaningful interpretation of imaging data from individual patients to assist diagnostic classification, inform prognosis, and enable the assessment of progressive changes compared to baseline scans. In an attempt to address the pragmatic demands of clinical imaging, a prospective computational neuroimaging study was undertaken in a cohort of patients across the spectrum of FTD phenotypes. Cortical changes were evaluated in a dual pipeline, using standard cortical thickness analyses and an individualised, z-score based approach to characterise subject-level disease burden. Phenotype-specific patterns of cortical atrophy were readily detected with both methodological approaches. Consistent with their clinical profiles, patients with bvFTD exhibited orbitofrontal, cingulate and dorsolateral prefrontal atrophy. Patients with ALS-FTD displayed precentral gyrus involvement, nfvPPA patients showed widespread cortical degeneration including insular and opercular regions and patients with svPPA exhibited relatively focal anterior temporal lobe atrophy. Cortical atrophy patterns were reliably detected in single individuals, and these maps were consistent with the clinical categorisation. Our preliminary data indicate that standard T1-weighted structural data from single patients may be utilised to generate maps of cortical atrophy. While the computational interpretation of single scans is challenging, it offers unrivalled insights compared to visual inspection. The quantitative evaluation of individual MRI data may aid diagnostic classification, clinical decision making, and assessing longitudinal changes. Springer US 2021-12-09 2022 /pmc/articles/PMC9107414/ /pubmed/34882275 http://dx.doi.org/10.1007/s11682-021-00523-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
McKenna, Mary Clare
Tahedl, Marlene
Lope, Jasmin
Chipika, Rangariroyashe H.
Li Hi Shing, Stacey
Doherty, Mark A.
Hengeveld, Jennifer C.
Vajda, Alice
McLaughlin, Russell L.
Hardiman, Orla
Hutchinson, Siobhan
Bede, Peter
Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title_full Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title_fullStr Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title_full_unstemmed Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title_short Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
title_sort mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107414/
https://www.ncbi.nlm.nih.gov/pubmed/34882275
http://dx.doi.org/10.1007/s11682-021-00523-7
work_keys_str_mv AT mckennamaryclare mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT tahedlmarlene mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT lopejasmin mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT chipikarangariroyasheh mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT lihishingstacey mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT dohertymarka mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT hengeveldjenniferc mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT vajdaalice mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT mclaughlinrusselll mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT hardimanorla mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT hutchinsonsiobhan mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials
AT bedepeter mappingcorticaldiseaseburdenatindividuallevelinfrontotemporaldementiaimplicationsforclinicalcareandpharmacologicaltrials